市場調査レポート

治療クラスの概要:難治性悪性血液疾患の治療

Treating Refractory Hematological Malignancies: Multiple Myeloma MM) New Treatment Options Driving In-Licensing and M&

発行 MP Advisors 商品コード 296612
出版日 ページ情報 英文 32 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
治療クラスの概要:難治性悪性血液疾患の治療 Treating Refractory Hematological Malignancies: Multiple Myeloma MM) New Treatment Options Driving In-Licensing and M&
出版日: 2014年02月25日 ページ情報: 英文 32 Pages
概要

当レポートでは、再発性・難治性多発性骨髄腫に対する現在のアンメットニーズとSOC(標準治療)の限界について調査し、治療領域における競合情勢と商業的機会の分析、臨床における早期・後期段階治療薬の包括的リストとそれらの作用機序・開発企業などを提供しており、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 疾病の概要

第3章 現在の治療基準

  • 再発性および/または難治性多発性骨髄腫
  • 新たに診断された多発性骨髄腫

第4章 認可製品

  • Revlimid (lenalidomide)
  • Kyprolis (carfilzomib)
  • POMALYST / IMNOVID (pomalidomide)

第5章 パイプライン:小分子

  • MLN9708
  • Panobinostat
  • Obatoclax
  • SNS01-T
  • Oprozomib
  • Rocilinostat
  • Afuresertib
  • KW-2478

第6章 モノクロナール抗体

  • Elotuzumab
  • Siltuximab
  • Daratumumab
  • MOR202
  • IPH2101

第7章 主な画期的出来事

  • 後期段階パイプラインに関するMPアドバイザーの見解
    • 発売スケジュールと市場潜在性
    • MM(多発性骨髄腫)におけるM&A/ライセンシング契約の促進因子

図表

目次
Product Code: TC14022201

Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs - Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival. However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of pts. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM) and Kyprolis (carfilzomib-CFZ) but is there room for more?

We expect a similar scenario to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML). Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium. The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing these therapy areas - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Table of Contents

Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

1. Executive Summary

2. Disease Overview

3. Current Standard of Care

  • 1. Relapsed and/or Refractory Multiple Myeloma
  • 2. Newly Diagnosed Multiple Myeloma

4. Approved Products

  • 1. Revlimid (lenalidomide)
  • 2. Kyprolis (carfilzomib)
  • 3. POMALYST / IMNOVID (pomalidomide)

5. Pipeline - Small Molecules

  • 1. MLN9708
  • 2. Panobinostat
  • 3. Obatoclax
  • 4. SNS01-T
  • 5. Oprozomib
  • 6. Rocilinostat
  • 7. Afuresertib
  • 8. KW-2478

6. Monoclonal Antibodies

  • 1. Elotuzumab
  • 2. Siltuximab
  • 3. Daratumumab
  • 4. MOR202
  • 5. IPH2101

7. Key Milestones

  • 1. MP Advisors' View on the Late-Stage Pipeline
    • 1. Launch Timeline and Market Potential
    • 2. Drivers of M&A / Licensing Deals in MM

TABLES

  • 1 Competitive Landscape - RRMM
  • 2 Data Comparison - Relapsed / Refractory Multiple Myeloma (RRMM)
  • 3 Competitive Landscape - NDMM
  • 4 Data Comparison - Newly Diagnosed Multiple Myeloma (NDMM)
  • 5 Data Comparison - Relapsed And Refractory Multiple Myeloma (RRMM)
  • 6 MM-003: POM+LoDEX vs. HiDEX in RRMM - Depth of Response
  • 7 Patent Expiries of Market Products
  • 8 Launch Timeline and Market Potential
  • 9 Select M&A and Licensing Deals in Last 6 Years - 2007 to 2013
  • 10 Select In-Licensing Opportunities: Small Molecules & mAbs

FIGURES

  • 1 Criteria For Progressive MM and Clinical Relapse
  • 2 Targets for novel targets incl. mAb in Multiple Myeloma
  • 3 SNS01-T: Reduction in Tumor Volume in RPMI 8226 Model

Table of Contents

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

1. Executive Summary

2. Disease Overview: MDS

  • 2.1. Unmet Need: MDS

3. Current Standard of Care

  • 3.1. Supportive Care: Hematopoietic Cytokine
  • 3.2. Low-Intensity Therapy
  • 3.3. High-Intensity Therapy
  • 3.4. Recurrent / Refractory or relapsed MDS

4. Disease Overview: AML

5. Current Standard of Care

  • 5.1. AML pts Younger than 60 years
  • 5.2. AML pts Older than 60 years

6. Unmet Need: AML

  • 6.1. Relapsed/ refractory AML

7. Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML

  • 7.1. Estybon
  • 7.2. Vosaroxin
  • 7.3. Quizartinib
  • 7.4. ADI-PEG 20
  • 7.5. BL-8040

8. Late-Stage pipeline Targeting 1st-line Lower Risk MDS

  • 8.1. Volasertib
  • 8.2. CPX-351
  • 8.3. Sapacitabine
  • 8.4. Oral Rigosrtib

9. Key Milestones of Drugs For RRMDS/RRAML in 2014-15

10. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML)

11. Drivers of M&A/Licensing Deals in MDS/AML

TABLES - MDS & AML

  • 1 Revised International Prognosis Scoring System (IPSS-R)
  • 2 Competitive Landscape: RR/ High-Risk MDS and RR AML
  • 3 Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML
  • 4 CPX-351: PhIIb Data for Patients with 2 Or 3 Risk Factors
  • 5 Launch Timeline and Market Potential
  • 6 Select M&A and Licensing Deals in Last 5 Years - 2007to 2012
  • 7 Select M&A and Licensing Deals Opportunities

FIGURES - MDS & AML

  • 1 Unmet Need For AML
  • 2 ITT Analysis: Survival Data for Refractory MDS Pts
  • 3 Best Bone Marrow (BM) Responses After Rig. IV
  • 4 Vosaroxin - Overall Survival Kaplan-Meier Curves
  • 5 Phase 3 VALOR Study Design - Vosaroxin in RR AML
  • 6 Overall Survival For AML Pts Less Than 60 Year Old with Flt3ITD Mutation
  • 7 Polo-Like Kinase 1 (PLK1): Key Regulator of Mitosis
Back to Top